These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 2555366)

  • 21. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23.
    Cordier M; Calender A; Billaud M; Zimber U; Rousselet G; Pavlish O; Banchereau J; Tursz T; Bornkamm G; Lenoir GM
    J Virol; 1990 Mar; 64(3):1002-13. PubMed ID: 2154588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction of iC3b with recombinant isotypic and chimeric forms of CR2.
    Kalli KR; Ahearn JM; Fearon DT
    J Immunol; 1991 Jul; 147(2):590-4. PubMed ID: 1830068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Purification of the Epstein-Barr virus/C3d complement receptor of human B lymphocytes: antigenic and functional properties of the purified protein.
    Nemerow GR; Siaw MF; Cooper NR
    J Virol; 1986 May; 58(2):709-12. PubMed ID: 2422399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutrophils express a receptor for iC3b, C3dg, and C3d that is distinct from CR1, CR2, and CR3.
    Vik DP; Fearon DT
    J Immunol; 1985 Apr; 134(4):2571-9. PubMed ID: 3156185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350.
    Young KA; Herbert AP; Barlow PN; Holers VM; Hannan JP
    J Virol; 2008 Nov; 82(22):11217-27. PubMed ID: 18786993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.
    Guthridge JM; Young K; Gipson MG; Sarrias MR; Szakonyi G; Chen XS; Malaspina A; Donoghue E; James JA; Lambris JD; Moir SA; Perkins SJ; Holers VM
    J Immunol; 2001 Nov; 167(10):5758-66. PubMed ID: 11698449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor, CD21).
    Esparza I; Becherer JD; Alsenz J; De la Hera A; Lao Z; Tsoukas CD; Lambris JD
    Eur J Immunol; 1991 Nov; 21(11):2829-38. PubMed ID: 1834472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21).
    Hannan JP
    Curr Protein Pept Sci; 2016; 17(5):463-87. PubMed ID: 26916158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human lymphocytes shed a soluble form of CD21 (the C3dg/Epstein-Barr virus receptor, CR2) that binds iC3b and CD23.
    Frémeaux-Bacchi V; Bernard I; Maillet F; Mani JC; Fontaine M; Bonnefoy JY; Kazatchkine MD; Fischer E
    Eur J Immunol; 1996 Jul; 26(7):1497-503. PubMed ID: 8766552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of three gp350/220 regions involved in Epstein-Barr virus invasion of host cells.
    Urquiza M; Lopez R; Patiño H; Rosas JE; Patarroyo ME
    J Biol Chem; 2005 Oct; 280(42):35598-605. PubMed ID: 16087675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis.
    Kovacs JM; Hannan JP; Eisenmesser EZ; Holers VM
    J Biol Chem; 2009 Apr; 284(14):9513-20. PubMed ID: 19164292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure and function of the B-lymphocyte Epstein-Barr virus/C3d receptor.
    Nemerow GR; Moore MD; Cooper NR
    Adv Cancer Res; 1990; 54():273-300. PubMed ID: 2136962
    [No Abstract]   [Full Text] [Related]  

  • 33. How Epstein-Barr virus envelope glycoprotein gp350 tricks the CR2? A molecular dynamics study.
    Bingöl EN; Taştekil I; Yay C; Keskin N; Ozbek P
    J Mol Graph Model; 2022 Jul; 114():108196. PubMed ID: 35500362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction between Epstein-Barr virus and a T cell line (HSB-2) via a receptor phenotypically distinct from complement receptor type 2.
    Hedrick JA; Watry D; Speiser C; O'Donnell P; Lambris JD; Tsoukas CD
    Eur J Immunol; 1992 May; 22(5):1123-31. PubMed ID: 1315687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Binding of the endogenously expressed Epstein-Barr virus (EBV) envelope glycoprotein gp350 with the viral receptor masks the major EBV-neutralizing epitope and affects gp350-specific ADCC.
    Khyatti M; Ahmad A; Blagdon M; Frade R; Menezes J
    J Leukoc Biol; 1998 Aug; 64(2):192-7. PubMed ID: 9715258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure of the Epstein-Barr virus major envelope glycoprotein.
    Szakonyi G; Klein MG; Hannan JP; Young KA; Ma RZ; Asokan R; Holers VM; Chen XS
    Nat Struct Mol Biol; 2006 Nov; 13(11):996-1001. PubMed ID: 17072314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of epitope expression and the functional repertoire of recombinant complement receptor 2 (CR2/CD21) in mouse and human cells.
    Carel JC; Frazier B; Ley TJ; Holers VM
    J Immunol; 1989 Aug; 143(3):923-30. PubMed ID: 2473114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tracing uptake of C3dg-conjugated antigen into B cells via complement receptor type 2 (CR2, CD21).
    Hess MW; Schwendinger MG; Eskelinen EL; Pfaller K; Pavelka M; Dierich MP; Prodinger WM
    Blood; 2000 Apr; 95(8):2617-23. PubMed ID: 10753842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).
    Clemenza L; Isenman DE
    J Immunol; 2000 Oct; 165(7):3839-48. PubMed ID: 11034390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stable expression and function of EBV/C3d receptor following genomic transfection into murine fibroblast L cells.
    Cantaloube JF; Piechaczyk M; Calender A; Lenoir G; Minty A; Carrière D; Fischer E; Poncelet P
    Eur J Immunol; 1990 Feb; 20(2):409-16. PubMed ID: 1690137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.